Pranlukast is indicated for the treatment of: Bronchial asthma, Symptoms of allergic rhinitis.

Pranlukast selectively antagonizes leukotriene D4 (LTD4) at cysteinyl leukotriene receptors in the human airway. It blocks the action of LTD4 at the CysLT1 receptor, thereby reducing airway edema, inhibiting smooth muscle contraction, and decreasing excessive secretion of thick, viscous mucus.

Child: 3.5 mg/kg bid.
Max dose: 10 mg/kg/day (not exceeding 450 mg daily).

Adults: Take 2 tablets (225 mg) at a time, twice a day after breakfast and dinner. The dosage may be adjusted according to your age and symptoms. Strictly follow the instructions.

Use in Children & Adolescents: There was a substantial benefit of adding pranlukast to usual therapy in asthmatic children.

Concurrent use with warfarin and other anticoagulants may lead to an increase in prothrombin time.

Pranlukast is contraindicated in acute asthma attacks and in patients with hepatic impairment or liver cirrhosis.

Common side effects may include headache, increased incidence of respiratory tract infections, gastrointestinal disturbances, generalized pain, fever, myalgia, and arthralgia.

Use of pranlukast is not associated with an increased risk of pregnancy loss, gestational diabetes, preeclampsia, low maternal weight gain, preterm birth, low Apgar scores, or reduced birth length. A slightly reduced birth weight observed in some cases may be related to maternal asthma severity and its control rather than the drug itself.

Caution is advised in patients with renal impairment. Possible elevation of liver enzymes may occur during treatment. Discontinue therapy in patients showing signs consistent with Churg-Strauss syndrome.

Store below 30°C. Protect from light and moisture. Keep all medicines out of the reach of children.